Literature DB >> 30775961

The relevance of persisters in tuberculosis drug discovery.

Soma Mandal1, Samuel Njikan1, Anuradha Kumar1, Julie V Early1, Tanya Parish1.   

Abstract

Bacterial persisters are a subpopulation of cells that exhibit phenotypic resistance during exposure to a lethal dose of antibiotics. They are difficult to target and thought to contribute to the long treatment duration required for tuberculosis. Understanding the molecular and cellular biology of persisters is critical to finding new tuberculosis drugs that shorten treatment. This review focuses on mycobacterial persisters and describes the challenges they pose in tuberculosis therapy, their characteristics and formation, how persistence leads to resistance, and the current approaches being used to target persisters within mycobacterial drug discovery.

Entities:  

Keywords:  antibiotics; drug discovery; mycobacteria; non-replicating organisms; persistence; tuberculosis

Year:  2019        PMID: 30775961     DOI: 10.1099/mic.0.000760

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  16 in total

Review 1.  Ribosome hibernation: a new molecular framework for targeting nonreplicating persisters of mycobacteria.

Authors:  Yunlong Li; Manjuli R Sharma; Ravi K Koripella; Nilesh K Banavali; Rajendra K Agrawal; Anil K Ojha
Journal:  Microbiology (Reading)       Date:  2021-02       Impact factor: 2.777

Review 2.  Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.

Authors:  Arijit Bhattacharya; Audrey Corbeil; Rubens L do Monte-Neto; Christopher Fernandez-Prada
Journal:  Genes (Basel)       Date:  2020-06-29       Impact factor: 4.096

Review 3.  Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

Authors:  José E S Nunes; Mario A Duque; Talita F de Freitas; Luiza Galina; Luis F S M Timmers; Cristiano V Bizarro; Pablo Machado; Luiz A Basso; Rodrigo G Ducati
Journal:  Molecules       Date:  2020-03-11       Impact factor: 4.411

Review 4.  Handling the Hurdles on the Way to Anti-tuberculosis Drug Development.

Authors:  Pedro F Dalberto; Eduardo V de Souza; Bruno L Abbadi; Christiano E Neves; Raoní S Rambo; Alessandro S Ramos; Fernanda S Macchi; Pablo Machado; Cristiano V Bizarro; Luiz A Basso
Journal:  Front Chem       Date:  2020-11-19       Impact factor: 5.221

5.  Phenoxyalkylimidazoles with an oxadiazole moiety are subject to efflux in Mycobacterium tuberculosis.

Authors:  Mai B Thayer; Tanya Parish
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

6.  Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis.

Authors:  Shashikant Srivastava; Kayle N Cirrincione; Devyani Deshpande; Tawanda Gumbo
Journal:  Front Pharmacol       Date:  2021-01-19       Impact factor: 5.810

7.  Trypanosoma cruzi amastigotes that persist in the colon during chronic stage murine infections have a reduced replication rate.

Authors:  Alexander I Ward; Francisco Olmo; Richard L Atherton; Martin C Taylor; John M Kelly
Journal:  Open Biol       Date:  2020-12-16       Impact factor: 6.411

8.  InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.

Authors:  Lindsay Flint; Aaron Korkegian; Tanya Parish
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

9.  Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy.

Authors:  Caroline G G Beltran; Tiaan Heunis; James Gallant; Rouxjeane Venter; Nelita du Plessis; Andre G Loxton; Matthias Trost; Jill Winter; Stephanus T Malherbe; Bavesh D Kana; Gerhard Walzl
Journal:  Front Cell Infect Microbiol       Date:  2020-08-25       Impact factor: 5.293

Review 10.  Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?

Authors:  Hyun-Eui Park; Wonsik Lee; Min-Kyoung Shin; Sung Jae Shin
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.